Technical Analysis for NLNK - NewLink Genetics Corporation

Grade Last Price % Change Price Change
grade F 1.66 5.73% 0.09
NLNK closed up 5.73 percent on Monday, May 20, 2019, on 74 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical NLNK trend table...

Date Alert Name Type % Chg
Bullish Engulfing Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
BB Squeeze Ended Range Expansion 5.73%
Gapped Down Weakness 5.73%
Lower Bollinger Band Touch Weakness 5.73%
Bollinger Band Squeeze Range Contraction 2.47%
Narrow Range Bar Range Contraction 2.47%

Older signals for NLNK ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
NewLink Genetics Corporation, a biopharmaceutical company, through its subsidiary, BioProtection Systems Corporation, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance cancer treatment options for patients and physicians. Its portfolio includes biologic and small-molecule immunotherapy product candidates based on proprietary HyperAcute immunotherapy technology for the treatment of various oncology indications. The company's lead product candidate, HyperAcute Pancreas cancer immunotherapy, is being studied in two Phase III clinical trials in surgically-resected pancreatic cancer patients. It is also developing HyperAcute Lung, which is being studied in a multi-center randomized, controlled Phase IIB/III clinical trials for non-small cell lung cancer; HyperAcute Melanoma that is in Phase II clinical trials for the treatment of melanoma; and a HyperAcute Renal cell cancer immunotherapy, as well as HyperAcute prostate and HyperAcute breast product candidates. In addition, the company is developing Indoximod, a small-molecule, orally bioavailable product candidate, which is being evaluated for the treatment of metastatic solid tumors in two Phase IB/II clinical trials; Provenge Indoximod that is in Phase II clinical trials for the treatment of prostate cancer; Docetaxel Indoximod, which is in Phase II clinical trials for the treatment of metastatic breast cancer; HyperAcute immunotherapy plus Indoximod that is in Phase IIB clinical trials; and NLG-919 IDO Pathway Inhibitor Candidate, which is in Phase I clinical trials for the treatment of metastatic solid tumors. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Medicine Biopharmaceutical Cancer Treatment Of Cancer Immunotherapy Prostate Cancer Non Small Cell Lung Cancer Cancer Immunotherapy Cancer Treatment Melanoma Metastatic Breast Cancer Bemcentinib Cancer Vaccine Metastatic Solid Tumors Treatment Of Prostate Cancer Treatment Of Metastatic Breast Cancer Immunotherapeutic Products Immunotherapy Technology Treatment Of Melanoma
Is NLNK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.61
52 Week Low 1.28
Average Volume 522,218
200-Day Moving Average 1.9908
50-Day Moving Average 1.7696
20-Day Moving Average 1.691
10-Day Moving Average 1.66
Average True Range 0.099
ADX 15.94
+DI 18.012
-DI 23.6024
Chandelier Exit (Long, 3 ATRs ) 1.523
Chandelier Exit (Short, 3 ATRs ) 1.827
Upper Bollinger Band 1.8194
Lower Bollinger Band 1.5626
Percent B (%b) 0.38
BandWidth 15.18628
MACD Line -0.0319
MACD Signal Line -0.0242
MACD Histogram -0.0077
Fundamentals Value
Market Cap 48.84 Million
Num Shares 29.4 Million
EPS -2.29
Price-to-Earnings (P/E) Ratio -0.72
Price-to-Sales 6.79
Price-to-Book 2.71
PEG Ratio -0.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.89
Resistance 3 (R3) 1.87 1.78 1.85
Resistance 2 (R2) 1.78 1.72 1.79 1.83
Resistance 1 (R1) 1.72 1.69 1.75 1.74 1.82
Pivot Point 1.63 1.63 1.65 1.64 1.63
Support 1 (S1) 1.57 1.57 1.60 1.59 1.50
Support 2 (S2) 1.48 1.54 1.49 1.49
Support 3 (S3) 1.42 1.48 1.47
Support 4 (S4) 1.44